Sign in
Taking people in United StatesPhase 3

Family donor immune cells for stubborn adenovirus or cytomegalovirus infection after stem cell transplant

Tests virus-fighting T cells from a family donor in young transplant recipients.

Key facts

Who runs it
New York Medical College
Where
Milwaukee and Valhalla, United StatesSee the 2 sites
Trial code
Registry title
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Status
Recruiting
Phase
Phase 3
People taking part
138 people, planned
Started
1 Sept 2026
Expected to end
1 Dec 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard of Care Antiviral medications
  • Viral CTLs
Record updated
11 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teens and young adults after a donor stem cell transplant. They must have an adenovirus (ADV) or cytomegalovirus (CMV) infection that has not gone away with antiviral medicine.

Age
0.01 to 30.00 years (1 day to 30 years)
Sex
All sexes can join.
Disease stage
ADV or CMV virus in the blood after a donor stem cell transplant. The virus level (> 1000 copies) keeps rising or stays after 7 days of antiviral therapy, or the person cannot tolerate the antiviral drugs, or the virus is resistant to them. Performance status must be >30% (Lansky under 16 years, Karnofsky over 16 years).
Earlier treatment
At least 7 days of antiviral therapy, or side effects from cidofovir (ADV), or from ganciclovir, foscarnet or cidofovir (CMV). No donor lymphocyte infusion (DLI) within 4 weeks before the cell infusion.
Biomarker or test result
ADV or CMV RT-PCR DNA > 1000 copies, or known resistance to cidofovir (ADV) or to ganciclovir and/or foscarnet (CMV). A family donor sharing > 3 HLA tissue markers whose T-cells react to the ADV or CMV test peptides.

Main reasons for not taking part

  • Acute graft-versus-host disease (GVHD) > grade 2, or moderate or extensive chronic GVHD
  • Taking steroids above 0.5 mg/kg prednisone equivalent at the time of the cell infusion
  • Known AIDS or uncontrolled HIV infection
  • Brain inflammation (encephalitis) and/or eye retinitis
  • Known allergy to iron dextran

The registry criteria, word for word

Show all 21 criteriaShow less

Other criteria

  • Patient Eligibility Cohort 1 (ADV) -Patients with ADV viremia (Cohort 1) post AlloHSCT with one or more of the following: Increasing or persistent ADV RT-PCR DNA (> 1000 ADV PCR copies) after 7 days of appropriate anti-viral therapy AND/OR Medical intolerance to anti-viral therapies including one or more of the following: > grade 2 renal insufficiency secondary to cidofovir and/or other > grade 2 toxicities secondary to cidofovir AND/OR Known resistance to cidofovir
  • Patient Eligibility (Cohort 2) (CMV)
  • -Patients with CMV viremia with one or more of the following: Increasing or persistent CMV RT-PCR DNA (>1000 copies) after 7 days of appropriate anti-viral therapy AND/OR Medical intolerance to anti-CMV antibiotic therapies: ANC < 500/mm3 secondary to ganciclovir AND/OR > grade 2 renal toxicity secondary to either foscarnet or cidofovir AND/OR Known resistance to ganciclovir and/or foscarnet
  • Consent: written informed consent given (by patient or legal representative) prior to any study related procedures
  • Performance Status >30% (Lansky < 16 yrs and Karnofsky > 16 years (BOTH COHORTS)
  • Age: 0.01 to 30.00 years (BOTH COHORTS)
  • Females of childbearing potential with a negative urine pregnancy test at study entry only (BOTH COHORTS)
  • Family related donor (> 3 HLA match) that screens positive for ADV5 MACS Peptivator (Cohort 1) or PP65CMV MACS Peptivator (Cohort 2); Donor Eligibility
  • Related donor available with a T-cell response to the ADV MACS PepTivators (Cohort 1) or CMV MACS PepTivator (Cohort 2). As defined in Appendix II, B, 8.2, the donor is considered suitable if the percentage of IFN+ T-cells is >0.01% after stimulation with ADV PepTivators (Cohort 1) or CMV PepTivators (Cohort 2)
  • Third-party related allogeneic donor: If original donor is not available or does not have a T-cell response to ADV MCAS PepTivator (Cohort 1) or CMV PepTivator (Cohort 2), third party allogeneic donor (family donor > 3 HLA A, B, DR match to recipient) with a T-cell response at least to the ADV MCAS PepTivator (Cohort 1) or CMV PepTivator (Cohort 2) AND
  • Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1) AND
  • Obtained informed consents by donor or donor legally authorized representative prior to donor collection; Patient Exclusion Criteria (Both Cohorts)
  • Patient with acute GVHD > grade 2 or moderate or extensive chronic GVHD at the time of CTL infusion
  • Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of CTL infusion
  • Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion
  • Patient with poor performance status determined by Karnofksy (patients > 16 yrs) or Lansky (patients < 16 years) score < 30%
  • Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory ADV or CMV infections
  • Any known medical condition which cold compromise participation in the study according to investigators assessment
  • Known AIDS or uncontrolled HIV infection
  • Known hypersensitivity to iron dextran
  • Encephalitis and/or retinitis

Where in United States

  • Medical College of WisconsinMilwaukee, United StatesContact: Julie An Talano, MDNot yet recruiting
  • New York Medical CollegeValhalla, United StatesContact: Mitchell S Cairo, MDTaking people

About the trial

What the trial wants to find out

Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.

The 2 groups in the trial

  • Standard of Care MedicationExisting treatment, for comparison

    Patients will receive standard of care antiviral therapy for CMV or ADV at the discretion of the physician.

    Treatment: Standard of Care Antiviral medications

  • Standard of Care Medication plus Cytotoxic T-Lymphocytes (CTLs)Treatment being tested

    Patients will be randomized to receiving standard of care antiviral therapy plus family matched donor derived CTLs.

    Treatment: Standard of Care Antiviral medications and Viral CTLs

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label Prospective Randomized Trial of Family Donor-Derived ADV or CMV CTLs Plus Standard of Care (SOC) vs SOC Alone in Children, Adolescents and Young Adults Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Refractory ADV or CMV Infection/Viremia
Plain-language title
Family donor immune cells for stubborn adenovirus or cytomegalovirus infection after stem cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 September 2026